New Chemical Entity
Rett Syndrome and other disorders
Pre-clinicalActive
Key Facts
About Unravel Biosciences
Unravel Biosciences is a private, preclinical-stage biotech founded in 2019 and based in Cambridge, Massachusetts. The company has developed a proprietary AI-driven platform that analyzes patient RNA signatures to create digital twin models, enabling the discovery of new therapeutic mechanisms and the repurposing of existing drugs. This approach aims to accelerate clinical validation and derisk development, as evidenced by its lead program for Rett syndrome which has received FDA Orphan Drug Designation and entered clinical testing. Unravel operates a hybrid business model, both discovering its own therapeutics and partnering its platform for drug discovery collaborations.
View full company profile